Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
Researchers at George Washington University take a look.
The experimental long-acting injectable regimen of cabotegravir and rilpivirine stands poised for approval.
Participants in a study were started on daily oral drugs and then half were switched over to long-acting meds.
This held true even among those with resistance to nucleoside/nucleotide reverse transcriptase inhibitors.
Research in human cells and mice found the antiretroviral suppressed harmful chronic inflammation linked to age-related disorders.
More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.
Gilead Sciences has released 96-week results from an ongoing double-blinded study comparing the two regimens.
So argued researchers behind a study that switched people from triple-antiretroviral regimens to Tivicay monotherapy.
This is according to a French study looking at discontinuations of Tivicay compared with Vitekta and Isentress.
A large ongoing study in Botswana has found that about 1 in 150 babies exposed to Tivicay at conception developed such birth defects.
Tivicay (dolutegravir) is a next-generation integrase inhibitor.
The integrase inhibitor is included in the single-tablet HIV regimens Triumeq and Juluca.
A recent meta-analysis compared side effects linked to Tivicay versus other antiretrovirals.
The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.